

Renal Cell Cancer Reference Handout

RCC Dx

RCC

Clear Cell Carcinoma (75%)

Non-Clear Cell Carcinoma (15%)

Chromophobe, Oncocytoma,
Papillary, Sarcomatoid, Medullary,
Collecting Duct

STAGING

T Stage

T1 = < 7 cm

T2 = > 7 cm

T3 = Perinephric tissue/tumor thrombus

T4 = Extra-renal, beyond Gerota's Fascia

Stages

Stage III = T3 or N+

Stage IV = T4

Clear Cell RCC Localized Tx Stage I-III

1. Observation

If small (< 2 cm) or limited life expectancy

2. Partial or Radical Nephrectomy

Partial: small (<7 cm/T1), elderly pt for nephron sparing)

Radical: large (>7/T2), complex, vascular or LN involvement

3. Stage III: Consider Adjuvant Sunitinib

Consider adjuvant sunitinib for high-risk pts

Clear Cell RCC Metastatic Tx

IMDC Prognostic Criteria

Clinical Risk Factors

< 1 year from dx to systemic tx
Poor PS/ECOG

Lab Risk Factors

Ca + CBC

Hypercalcemia
Neutrophilia
Anemia
Thrombocytosis

1 point per risk factor

Favorable [0 points]

Avg OS = 37 months

Intermediate [1-2 points]

Avg OS = 28 months

Poor [3-6 points]

Avg OS = 9 months

FAVORABLE RISK

1. TKI + IO

Axitinib + Pembrolizumab

Lenvatinib + Pembrolizumab

Cabozantinib + Nivolumab

Oligometastatic:

Consider resection of metastasis:

if solitary, resectable site (ex: lung lesion)

INTERMEDIATE RISK

POOR RISK

1. TKIs + IO

Axitinib + Pembrolizumab

Lenvatinib + Pembrolizumab

Cabozantinib + Nivolumab

2. TKIs

Cabozantinib

3. IO

Ipilimumab + Nivolumab